ReviewWorld journal of gastrointestinal pathophysiology2019
Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings.
Review in World journal of gastrointestinal pathophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease.The oncologist · 2025Article
- Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report.Immunotherapy · 2025Article
- Cemiplimab-Induced Colitis Causing Hypovolemic Shock: A Case Report and Literature Review.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Early identification and multidisciplinary management of immune checkpoint inhibitors associated colitis can improve patient outcomes.World journal of gastrointestinal surgery · 2025Article
- Treatment of immune checkpoint inhibitor-related colitis: a narrative review.Translational cancer research · 2024Review
- Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events.Clinical endoscopy · 2024Review
- Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach.Inflammatory bowel diseases · 2024Review
- New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis.World journal of clinical cases · 2024Review
- Pembrolizumab-Induced Colitis and Diarrhea in the Treatment of Sporadic Colorectal Cancer: A Case Report.Cureus · 2024Article
- Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.Journal of cancer research and clinical oncology · 2023Article
- Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.Intestinal research · 2023Article
- Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Article
- Nivolumab dose escalation triggered immune checkpoint inhibitor-induced colitis after 147 weeks of prolonged stable use in a patient with lung cancer: a case report.Clinical journal of gastroenterology · 2022Article
- A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review.OncoTargets and therapy · 2022Article
- Assessment of the incidence and etiology of nosocomial diarrhea in a medical ward in Iraq.Journal of medicine and life · 2022Article
- The multifaceted roles of common gut microbiota in immune checkpoint inhibitor-mediated colitis: From mechanism to clinical application.Frontiers in immunology · 2022Review
- Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.European radiology · 2021Article
- Immune Checkpoint Inhibitor-Induced Gastrointestinal Toxicity: The Opinion of a Gastroenterologist.Cureus · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The indications of immune checkpoint inhibitors (ICPIs) for cancer treatment have rapidly expanded, and their use is increasing in clinical settings worldwide. Despite the considerable clinical benefits of ICPIs, frequent immune-related adverse events (irAEs) have become nonnegligible concerns. Among irAEs, ICPI-induced colitis/diarrhea is frequent and recognized not only by oncologists but also by gastroenterologists or endoscopists. The endoscopic findings show similarity to those of inflammatory bowel disease to a certain extent, particularly ulcerative colitis, but do not seem to be identical. The pathological findings of ICPI-induced colitis may vary among drug classes. They show acute or chronic inflammation, but it may depend on the time of colitis suggested by colonoscopy, including biopsy or treatment intervention. In the case of chronic inflammation determined by biopsy, the endoscopy findings may overlap with those of inflammatory bowel disease. Here, we provide a comprehensive review of ICPI-induced colitis based on clinical, endoscopic and pathologic findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.